LEGN
Legend Biotech Corporation
Biotechnology
Market Cap$5.19B
5Y Perf.-33.9%
Compare Stocks
5 / 10Try these comparisons:
Stock Comparison
LEGN vs FATE vs CRSP vs BEAM vs NTLA
Revenue, margins, valuation, and 5-year total return — side by side.
FATE
Fate Therapeutics, Inc.
Biotechnology
Market Cap$276M
5Y Perf.-93.0%
CRSP
CRISPR Therapeutics AG
Biotechnology
Market Cap$5.29B
5Y Perf.-25.4%
BEAM
Beam Therapeutics Inc.
Biotechnology
Market Cap$3.32B
5Y Perf.+15.4%
NTLA
Intellia Therapeutics, Inc.
Biotechnology
Market Cap$1.66B
5Y Perf.-33.0%
LEGN vs FATE vs CRSP vs BEAM vs NTLA — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | LEGN | FATE | CRSP | BEAM | NTLA |
|---|---|---|---|---|---|
| Industry | Biotechnology | Biotechnology | Biotechnology | Biotechnology | Biotechnology |
| Market Cap | $5.19B | $276M | $5.29B | $3.32B | $1.66B |
| Revenue (TTM) | $1.03B | $7M | $4M | $132M | $68M |
| Net Income (TTM) | $-297M | $-136M | $-569M | $-65M | $-413M |
| Gross Margin | 60.3% | — | -41.7% | -64.2% | -25.6% |
| Operating Margin | -13.2% | -22.2% | -134.1% | -281.0% | -6.5% |
| Forward P/E | 116.2x | — | — | — | — |
| Total Debt | $414M | $78M | $395M | $294M | $93M |
| Cash & Equiv. | $902M | $47M | $355M | $295M | $155M |
LEGN vs FATE vs CRSP vs BEAM vs NTLA — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
LEGN
FATE
CRSP
BEAM
NTLA
| Stock | Jun 20 | May 26 | Return |
|---|---|---|---|
| Legend Biotech Corp… (LEGN) | 100 | 66.1 | -33.9% |
| Fate Therapeutics, … (FATE) | 100 | 7.0 | -93.0% |
| CRISPR Therapeutics… (CRSP) | 100 | 74.6 | -25.4% |
| Beam Therapeutics I… (BEAM) | 100 | 115.4 | +15.4% |
| Intellia Therapeuti… (NTLA) | 100 | 67.0 | -33.0% |
Price return only. Dividends and distributions are not included.
Quick Verdict: LEGN vs FATE vs CRSP vs BEAM vs NTLA
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: LEGN and BEAM are tied at the top with 2 categories each (5-stock set) — the right choice depends on your priorities. Beam Therapeutics Inc. is the stronger pick specifically for growth and revenue expansion and operational efficiency and capital deployment. FATE also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
LEGN
Legend Biotech Corporation
The Income Pick
LEGN carries the broadest edge in this set and is the clearest fit for income & stability.
- beta 0.76
- -28.8% margin vs CRSP's -138.6%
- Beta 0.76 vs NTLA's 2.21
Best for: income & stability
FATE
Fate Therapeutics, Inc.
The Momentum Pick
FATE ranks third and is worth considering specifically for momentum.
- +132.0% vs LEGN's -12.2%
Best for: momentum
CRSP
CRISPR Therapeutics AG
The Long-Run Compounder
CRSP is the clearest fit if your priority is long-term compounding and sleep-well-at-night.
- 289.1% 10Y total return vs BEAM's 72.4%
- Lower volatility, beta 1.87, Low D/E 20.5%, current ratio 13.32x
- Beta 1.87, current ratio 13.32x
Best for: long-term compounding and sleep-well-at-night
BEAM
Beam Therapeutics Inc.
The Growth Play
BEAM is the #2 pick in this set and the best alternative if growth exposure is your priority.
- Rev growth 120.0%, EPS growth 82.3%, 3Y rev CAGR 31.9%
- 120.0% revenue growth vs CRSP's -90.0%
- -4.6% ROA vs NTLA's -45.2%, ROIC -31.1% vs -44.0%
Best for: growth exposure
NTLA
Intellia Therapeutics, Inc.
The Healthcare Pick
Among these 5 stocks, NTLA doesn't own a clear edge in any measured category.
Best for: healthcare exposure
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | BEAM | 120.0% revenue growth vs CRSP's -90.0% |
| Quality / Margins | LEGN | -28.8% margin vs CRSP's -138.6% |
| Stability / Safety | LEGN | Beta 0.76 vs NTLA's 2.21 |
| Dividends | Tie | None of these 5 stocks pay a meaningful dividend |
| Momentum (1Y) | FATE | +132.0% vs LEGN's -12.2% |
| Efficiency (ROA) | BEAM | -4.6% ROA vs NTLA's -45.2%, ROIC -31.1% vs -44.0% |
LEGN vs FATE vs CRSP vs BEAM vs NTLA — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2021
FY 2023
FY 2025
Segment breakdown not available.
Segment breakdown not available.
LEGN vs FATE vs CRSP vs BEAM vs NTLA — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLLEGNLAGGINGNTLA
Who Leads Where
LEGN leads in 1 of 6 categories
BEAM leads 1 • CRSP leads 1 • FATE leads 0 • NTLA leads 0 • 2 tied
Explore the data ↓NTLAIntellia Therapeutics…
0leads
FATEFate Therapeutics, In…
0leads
BEAMBeam Therapeutics Inc.
1leads
CRSPCRISPR Therapeutics AG
1leads
LEGNLegend Biotech Corpor…
1leads
6 Total Categories
CATEGORYLEADERvs CRSPvs BEAMMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
LEGN4/6
Valuation MetricsMultiples, price ratios, and targets
Tied
—
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
BEAM4/9
Total Returns1Y, 3Y, 5Y total returns with dividends
CRSP3/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
LEGN leads this category, winning 4 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
LEGN is the larger business by revenue, generating $1.0B annually — 251.1x CRSP's $4M. LEGN is the more profitable business, keeping -28.8% of every revenue dollar as net income compared to CRSP's -138.6%. On growth, NTLA holds the edge at +78.8% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | LEGNLegend Biotech Co… | FATEFate Therapeutics… | CRSPCRISPR Therapeuti… | BEAMBeam Therapeutics… | NTLAIntellia Therapeu… |
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.0B | $7M | $4M | $132M | $68M |
| EBITDAEarnings before interest/tax | -$107M | -$148M | -$535M | -$355M | -$431M |
| Net IncomeAfter-tax profit | -$297M | -$136M | -$569M | -$65M | -$413M |
| Free Cash FlowCash after capex | -$231M | -$88M | -$401M | -$384M | -$396M |
| Gross MarginGross profit ÷ Revenue | +60.3% | — | -41.7% | -64.2% | -25.6% |
| Operating MarginEBIT ÷ Revenue | -13.2% | -22.2% | -134.1% | -2.8% | -6.5% |
| Net MarginNet income ÷ Revenue | -28.8% | -20.5% | -138.6% | -49.2% | -6.1% |
| FCF MarginFCF ÷ Revenue | -22.4% | -13.2% | -97.8% | -2.9% | -5.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +64.9% | -26.4% | +68.6% | -100.0% | +78.8% |
| EPS Growth (YoY)Latest quarter vs prior year | -2.2% | +38.6% | +19.0% | +26.6% | +34.6% |
LEGN leads this category, winning 4 of 6 comparable metrics.
Valuation Metrics
Evenly matched — LEGN and FATE and BEAM each lead in 1 of 3 comparable metrics.
Valuation Metrics
| Metric | LEGNLegend Biotech Co… | FATEFate Therapeutics… | CRSPCRISPR Therapeuti… | BEAMBeam Therapeutics… | NTLAIntellia Therapeu… |
|---|---|---|---|---|---|
| Market CapShares × price | $5.2B | $276M | $5.3B | $3.3B | $1.7B |
| Enterprise ValueMkt cap + debt − cash | $4.7B | $307M | $5.3B | $3.3B | $1.6B |
| Trailing P/EPrice ÷ TTM EPS | -8.73x | -2.08x | -8.47x | -39.90x | -3.70x |
| Forward P/EPrice ÷ next-FY EPS est. | 116.25x | — | — | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — | — | — | — |
| EV / EBITDAEnterprise value multiple | — | — | — | — | — |
| Price / SalesMarket cap ÷ Revenue | 5.03x | 41.49x | 1506.63x | 23.76x | 24.60x |
| Price / BookPrice ÷ Book value/share | 2.59x | 1.37x | 2.57x | 2.58x | 2.27x |
| Price / FCFMarket cap ÷ FCF | — | — | — | — | — |
Evenly matched — LEGN and FATE and BEAM each lead in 1 of 3 comparable metrics.
Profitability & Efficiency
BEAM leads this category, winning 4 of 9 comparable metrics.
Profitability & Efficiency
BEAM delivers a -5.9% return on equity — every $100 of shareholder capital generates $-6 in annual profit, vs $-66 for FATE. NTLA carries lower financial leverage with a 0.14x debt-to-equity ratio, signaling a more conservative balance sheet compared to LEGN's 0.41x. On the Piotroski fundamental quality scale (0–9), BEAM scores 4/9 vs CRSP's 1/9, reflecting mixed financial health.
| Metric | LEGNLegend Biotech Co… | FATEFate Therapeutics… | CRSPCRISPR Therapeuti… | BEAMBeam Therapeutics… | NTLAIntellia Therapeu… |
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | -29.2% | -65.8% | -30.9% | -5.9% | -56.6% |
| ROA (TTM)Return on assets | -17.6% | -42.7% | -24.5% | -4.6% | -45.2% |
| ROICReturn on invested capital | -12.7% | -36.5% | -22.3% | -31.1% | -44.0% |
| ROCEReturn on capital employed | -11.0% | -43.1% | -26.6% | -33.3% | -48.5% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 2 | 1 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.41x | 0.38x | 0.21x | 0.24x | 0.14x |
| Net DebtTotal debt minus cash | -$488M | $31M | $40M | -$1M | -$62M |
| Cash & Equiv.Liquid assets | $902M | $47M | $355M | $295M | $155M |
| Total DebtShort + long-term debt | $414M | $78M | $395M | $294M | $93M |
| Interest CoverageEBIT ÷ Interest expense | -12.69x | — | — | 1.08x | — |
BEAM leads this category, winning 4 of 9 comparable metrics.
Total Returns (Dividends Reinvested)
CRSP leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in LEGN five years ago would be worth $9,584 today (with dividends reinvested), compared to $316 for FATE. Over the past 12 months, FATE leads with a +132.0% total return vs LEGN's -12.2%. The 3-year compound annual growth rate (CAGR) favors CRSP at -0.7% vs NTLA's -31.2% — a key indicator of consistent wealth creation.
| Metric | LEGNLegend Biotech Co… | FATEFate Therapeutics… | CRSPCRISPR Therapeuti… | BEAMBeam Therapeutics… | NTLAIntellia Therapeu… |
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +30.7% | +141.4% | +2.0% | +19.1% | +53.0% |
| 1-Year ReturnPast 12 months | -12.2% | +132.0% | +51.7% | +87.4% | +70.2% |
| 3-Year ReturnCumulative with dividends | -59.1% | -56.1% | -2.0% | -3.1% | -67.4% |
| 5-Year ReturnCumulative with dividends | -4.2% | -96.8% | -46.0% | -49.6% | -76.9% |
| 10-Year ReturnCumulative with dividends | -24.0% | +38.2% | +289.1% | +72.4% | -41.3% |
| CAGR (3Y)Annualised 3-year return | -25.8% | -24.0% | -0.7% | -1.0% | -31.2% |
CRSP leads this category, winning 3 of 6 comparable metrics.
Risk & Volatility
Evenly matched — LEGN and FATE each lead in 1 of 2 comparable metrics.
Risk & Volatility
LEGN is the less volatile stock with a 0.76 beta — it tends to amplify market swings less than NTLA's 2.21 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. FATE currently trades 97.0% from its 52-week high vs NTLA's 49.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | LEGNLegend Biotech Co… | FATEFate Therapeutics… | CRSPCRISPR Therapeuti… | BEAMBeam Therapeutics… | NTLAIntellia Therapeu… |
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.76x | 1.99x | 1.87x | 2.08x | 2.21x |
| 52-Week HighHighest price in past year | $45.30 | $2.46 | $78.48 | $36.44 | $28.25 |
| 52-Week LowLowest price in past year | $16.24 | $0.91 | $34.12 | $15.35 | $6.83 |
| % of 52W HighCurrent price vs 52-week peak | +62.1% | +97.0% | +69.9% | +88.7% | +49.9% |
| RSI (14)Momentum oscillator 0–100 | 74.8 | 82.9 | 49.4 | 57.7 | 49.5 |
| Avg Volume (50D)Average daily shares traded | 1.9M | 1.9M | 1.9M | 2.0M | 5.3M |
Evenly matched — LEGN and FATE each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
Analyst consensus: LEGN as "Buy", FATE as "Buy", CRSP as "Buy", BEAM as "Buy", NTLA as "Buy". Consensus price targets imply 1552.7% upside for FATE (target: $40) vs 14.9% for CRSP (target: $63).
| Metric | LEGNLegend Biotech Co… | FATEFate Therapeutics… | CRSPCRISPR Therapeuti… | BEAMBeam Therapeutics… | NTLAIntellia Therapeu… |
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $57.89 | $39.50 | $63.00 | $40.83 | $20.00 |
| # AnalystsCovering analysts | 19 | 31 | 38 | 27 | 39 |
| Dividend YieldAnnual dividend ÷ price | — | — | — | — | — |
| Dividend StreakConsecutive years of raises | — | — | — | — | — |
| Dividend / ShareAnnual DPS | — | — | — | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
LEGN leads in 1 of 6 categories (Income & Cash Flow). BEAM leads in 1 (Profitability & Efficiency). 2 tied.
Best OverallLegend Biotech Corporation (LEGN)Leads 1 of 6 categories
Loading custom metrics...
LEGN vs FATE vs CRSP vs BEAM vs NTLA: Key Questions Answered
9 questions · data-driven answers · updated daily
01Is LEGN or FATE or CRSP or BEAM or NTLA a better buy right now?
For growth investors, Beam Therapeutics Inc.
(BEAM) is the stronger pick with 120. 0% revenue growth year-over-year, versus -90. 0% for CRISPR Therapeutics AG (CRSP). Analysts rate Legend Biotech Corporation (LEGN) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — LEGN or FATE or CRSP or BEAM or NTLA?
Over the past 5 years, Legend Biotech Corporation (LEGN) delivered a total return of -4.
2%, compared to -96. 8% for Fate Therapeutics, Inc. (FATE). Over 10 years, the gap is even starker: CRSP returned +289. 1% versus NTLA's -41. 3%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — LEGN or FATE or CRSP or BEAM or NTLA?
By beta (market sensitivity over 5 years), Legend Biotech Corporation (LEGN) is the lower-risk stock at 0.
76β versus Intellia Therapeutics, Inc. 's 2. 21β — meaning NTLA is approximately 193% more volatile than LEGN relative to the S&P 500. On balance sheet safety, Intellia Therapeutics, Inc. (NTLA) carries a lower debt/equity ratio of 14% versus 41% for Legend Biotech Corporation — giving it more financial flexibility in a downturn.
04Which is growing faster — LEGN or FATE or CRSP or BEAM or NTLA?
By revenue growth (latest reported year), Beam Therapeutics Inc.
(BEAM) is pulling ahead at 120. 0% versus -90. 0% for CRISPR Therapeutics AG (CRSP). On earnings-per-share growth, the picture is similar: Beam Therapeutics Inc. grew EPS 82. 3% year-over-year, compared to -66. 0% for Legend Biotech Corporation. Over a 3-year CAGR, LEGN leads at 106. 6% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
05Which has better profit margins — LEGN or FATE or CRSP or BEAM or NTLA?
Legend Biotech Corporation (LEGN) is the more profitable company, earning -28.
8% net margin versus -165. 7% for CRISPR Therapeutics AG — meaning it keeps -28. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LEGN leads at -13. 3% versus -161. 9% for CRSP. At the gross margin level — before operating expenses — BEAM leads at 84. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is LEGN or FATE or CRSP or BEAM or NTLA more undervalued right now?
Analyst consensus price targets imply the most upside for FATE: 1552.
7% to $39. 50.
07Which pays a better dividend — LEGN or FATE or CRSP or BEAM or NTLA?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is LEGN or FATE or CRSP or BEAM or NTLA better for a retirement portfolio?
For long-horizon retirement investors, Legend Biotech Corporation (LEGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
76)). Intellia Therapeutics, Inc. (NTLA) carries a higher beta of 2. 21 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LEGN: -24. 0%, NTLA: -41. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between LEGN and FATE and CRSP and BEAM and NTLA?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: LEGN is a small-cap high-growth stock; FATE is a small-cap quality compounder stock; CRSP is a small-cap quality compounder stock; BEAM is a small-cap high-growth stock; NTLA is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
Revenue Growth>
%
(LEGN: 64.9% · FATE: -26.4%)You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.